BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the first patients have been enrolled in a Phase 1 clinical trial to evaluate its novel immunotherapy ADU-623 in patients with high-grade glioma, a form of brain cancer. The trial is being conducted by leading investigators at the Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Oregon. The project has been funded by grants from the Kuni Foundation and Providence Portland Medical Foundation.
Help employers find you! Check out all the jobs and post your resume.
